Clinical Trials
6
Active:4
Completed:1
Trial Phases
2 Phases
Phase 1:5
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (83.3%)Phase 2
1 (16.7%)Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease
Phase 1
Recruiting
- Conditions
- First in Man Study to Evaluate Initial Safety
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Gliknik Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05318534
- Locations
- 🇬🇧
Fortrea Clinical Research Unit Ltd, Leeds, United Kingdom
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Phase 2
Completed
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Gliknik Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02873819
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇭🇺National Institute of Oncology, Budapest, Hungary
🇭🇺Semmelweis University, Budapest, Hungary
News
No news found